| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bax channel blocker | CTRPv2 | pan-cancer | AAC | 0.031 | 0.4 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.043 | 0.4 |
| mRNA | necrosulfonamide | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | Tamoxifen | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | GW-405833 | CTRPv2 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | NPK76-II-72-1 | GDSC1000 | pan-cancer | AAC | -0.023 | 0.4 |
| mRNA | SL 0101-1 | GDSC1000 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.028 | 0.4 |
| mRNA | 968 | CTRPv2 | pan-cancer | AAC | 0.055 | 0.4 |